PMID- 34418225
OWN - NLM
STAT- MEDLINE
DCOM- 20220331
LR  - 20220531
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 34
IP  - 6
DP  - 2021 Nov
TI  - Effectiveness of brodalumab after previous treatment failure of interleukin-17A 
      inhibitors in patients with psoriasis.
PG  - e15106
LID - 10.1111/dth.15106 [doi]
AB  - Studies on switch between interleukin (IL)-17 inhibitors are scarce. We assessed 
      the effectiveness of brodalumab in patients with previous treatment failure of 
      IL-17A inhibitor(s). Patients with psoriasis and previous treatment failure of an 
      IL-17A inhibitor were treated with brodalumab at standard dose. Effectiveness was 
      assessed after 12, 26, and 52 weeks of treatment. The primary outcome was the 
      proportion of patients that had achieved an absolute psoriasis area and severity 
      index (PASI) </=2 and/or a relative reduction of PASI of 75% (PASI75) at week 12. 
      Plasma cytokine levels were measured at baseline and after 12 weeks of treatment. 
      In total, 20 patients were included, seven (35%) were female, the median age was 
      50 years, and the median baseline PASI was 13.5. Analyzing the data using 
      nonresponder imputation, 14 (70%) patients had achieved either PASI75 and/or PASI 
      </=2, 8 (40%) had achieved PASI90, and three (15%) had achieved PASI100 at week 12. 
      In total, nine patients (45%) completed the 52-weeks trial and seven patients 
      (35%) still had PASI75 throughout 52 weeks. Seventeen out of 20 patients 
      experienced any adverse events (AEs) during 52 weeks with no serious AEs or 
      deaths. Patients responding to treatment had lower levels of tumor necrosis 
      factor (TNF)-alpha and IL-6 at baseline compared with those who did not respond to 
      treatment (TNF-alpha, p = 0.041, IL-6, p = 0.0054). In conclusion, treatment with 
      brodalumab despite previous treatment failure with an IL-17A inhibitor can be 
      effective and well-tolerated.
CI  - (c) 2021 Wiley Periodicals LLC.
FAU - Loft, Nikolai
AU  - Loft N
AUID- ORCID: 0000-0002-2950-3280
AD  - Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev 
      and Gentofte, Copenhagen, Denmark.
AD  - Copenhagen Research Group for Inflammatory Skin, Copenhagen University Hospital - 
      Herlev and Gentofte, Copenhagen, Denmark.
FAU - Bregnhoj, Anne
AU  - Bregnhoj A
AD  - Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
AD  - Institute of Clinical Medicine, Aarhus University, Denmark.
FAU - Fage, Simon
AU  - Fage S
AD  - Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
FAU - Nielsen, Claus Henrik
AU  - Nielsen CH
AD  - Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, 
      Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
FAU - Enevold, Christian
AU  - Enevold C
AD  - Institute for Inflammation Research, Center for Rheumatology and Spine Diseases, 
      Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
FAU - Zachariae, Claus
AU  - Zachariae C
AD  - Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev 
      and Gentofte, Copenhagen, Denmark.
AD  - Copenhagen Research Group for Inflammatory Skin, Copenhagen University Hospital - 
      Herlev and Gentofte, Copenhagen, Denmark.
AD  - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
FAU - Iversen, Lars
AU  - Iversen L
AD  - Department of Dermatology, Aarhus University Hospital, Aarhus, Denmark.
AD  - Institute of Clinical Medicine, Aarhus University, Denmark.
FAU - Skov, Lone
AU  - Skov L
AD  - Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev 
      and Gentofte, Copenhagen, Denmark.
AD  - Copenhagen Research Group for Inflammatory Skin, Copenhagen University Hospital - 
      Herlev and Gentofte, Copenhagen, Denmark.
AD  - Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
DEP - 20210827
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Interleukin Inhibitors)
RN  - 0 (Interleukin-17)
RN  - 6ZA31Y954Z (brodalumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - Female
MH  - Humans
MH  - Interleukin Inhibitors
MH  - *Interleukin-17
MH  - Male
MH  - Middle Aged
MH  - *Psoriasis/diagnosis/drug therapy/pathology
MH  - Severity of Illness Index
MH  - Treatment Failure
MH  - Treatment Outcome
OTO - NOTNLM
OT  - psoriasis
OT  - therapy - systemic
EDAT- 2021/08/22 06:00
MHDA- 2022/04/01 06:00
CRDT- 2021/08/21 17:16
PHST- 2021/06/30 00:00 [received]
PHST- 2021/08/16 00:00 [accepted]
PHST- 2021/08/22 06:00 [pubmed]
PHST- 2022/04/01 06:00 [medline]
PHST- 2021/08/21 17:16 [entrez]
AID - 10.1111/dth.15106 [doi]
PST - ppublish
SO  - Dermatol Ther. 2021 Nov;34(6):e15106. doi: 10.1111/dth.15106. Epub 2021 Aug 27.